Treatment of Strongyloides Infection

Stopped early · Phase 3

Conditions studied: Strongyloides Stercoralis Infection, Strongyloidiasis

In brief

The aim of this study is to evaluate the serologic response in patients with S. stercoralis infection after treatment with a regimen of two single doses of 200 µg/kg of ivermectin given 2 weeks apart versus a regimen of two single doses of 200 µg/kg of ivermectin given in two consecutive days.

Key facts

Study ID

NCT03605758

Run by

Albert Einstein College of Medicine

People needed

51

Starts

2012-05-01

Expected to finish

2015-02-05

Last updated by the study team

2023-11-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age
• Positive for Strongyloides serology infection (as determined by ELISA)

You may not qualify if…

• Severe intestinal Strongyloides infection
• Disseminated Strongyloidiasis infection
• Pregnant and breastfeeding women
• HTLV-1 co-infection
• Patients with indeterminate results on Strongyloides serology
• Patients who are immunosuppressed
• Unable to read and understand consent form

Where it is running

• Jacobi Medical Center — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.